報價延遲最少15分鐘:2025/06/28 13:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
45.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.07/2.59
|
|
企業價值
3.09B
|
| 資產負債 |
|
每股賬面淨值
18.97
|
| 現金流量 |
|
現金流量率
0.08
|
| 損益表 |
|
收益
1.25B
|
|
每股收益
20.51
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/28 13:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world. |